Brain Scan Breakthrough Helps Predict
Total Page:16
File Type:pdf, Size:1020Kb
Bi Board Look out for these Upcoming Issues 2006 Australia Brain Scan Breakthrough Helps Predict Schizophrenia University of Melbourne researchers have become the fi rst in the world to show that brain scans can be used to predict how well young people will recover from early 15 Nov Special Issue on psychotic episodes that occur in mental illnesses such as Clinical Trials in Asia Pacifi c schizophrenia. 30 Nov Biostatistics A team from the University’s Melbourne Neuropsychiatry Center (MNC) and ORYGEN Research Center has made the breakthrough. Their research shows that levels of a certain 15 Dec Lipodomics chemical in the brain can predict how a young person experiencing their fi rst psychotic episode is likely to be 30 Dec Special Issue on affected over the next few years. The Melbourne scientists Bioinformatics in Asia Pacifi c compared the brain scans of 46 psychiatric patients with their health records over two years. The researchers used a technique known as MR spectroscopy, in which MRI scans are used to measure the concentration of chemicals in the brain. Findings of the research are published this month in the international journal the Archives of General Psychiatry. International Bio Partnering The Victorian Government has engaged a biotechnology industry consultant, Intersuisse Bioscience, to help build Victoria’s profi le as a world-class biotechnology center and to encourage European biotechnology companies to invest in Victoria. Intersuisse Bioscience will act as an international facilitator to bring international companies (focusing on those in Europe and the UK) into useful contact with those in Victoria, such that new commercial collaborations are created and developed. Bi Board New Generation Heart Assist effective monitoring and licensing framework to Devices Show Promise for prevent improper and unacceptable practices and continue a range of prohibitions including the ban Patients on reproductive cloning. Australian heart assist device company Sunshine Heart, Inc has revolutionize treatment options for patients with congestive heart failure with its new Peter Maccallum Cancer Center discovery of heart assist devices which will be free and Affymetrix Initiate Five-Year of external attachments. Congestive heart failure is Research Collaboration a progressively worsening condition characterized Affymetrix Inc. announced that it has entered into by shortness of breath with mild exercise, fatigue, five-year collaboration with the Peter MacCallum dizziness and fluid retention. Cancer Centre to analyze genomic information across Sunshine Heart’s C-PulseTM is an implantable, non- large patient samples. Under terms of the agreement, blood contacting heart assist device for the treatment Peter Mac researchers will use Affymetrix GeneChip® of people with heart failure. The C-PulseTM has been microarray technology for translational research designed to increase blood supply to both the body projects, beginning with studies on ovarian cancer and the heart itself, simultaneously reducing the and carcinoma of unknown primaries. Peter Mac strain on the heart and relieving patient’s symptoms. researchers will use Affymetrix GeneChip technology The C-PulseTM is aimed at patients with moderate to to perform large-scale clinical studies. The Affymetrix severe heart failure and because it does not come into technology will enable them to more rapidly discover contact with blood, the risk of clotting and bleeding RNA and DNA patterns that can better classify, complications are reduced and the device is safe to manage and treat complex diseases. turn on and off as desired. Sunshine Heart is working with the Allegheny- Portland Orthopaedics’ $360K Singer Research Institute (ASRI) in Pittsburgh, USA US Hip order to evaluate the feasibility of using Allegheny’s unique Portland Orthopaedics Limited has received its muscle energy converter (MEC) to power the C-PulseTM third order from US distributor Plus Orthopedics heart-assist device. Researchers at ASRI have invented Inc with the new order requesting a further A$360,000 a completely self-contained hydraulic pump that of primary hip replacements for immediate delivery. requires no external power source. Called a muscle This is Portland’s second order for the M-COR primary energy converter, or MEC, the device turns skeletal hip. The three orders over three months totals A2.47 muscles into living batteries, harnessing their vast million compared to total sales in the year to June stores of mechanical energy to power an implant. Once 2006 of A$1.63 million. Portland’s M-COR primary situated in the chest, the titanium device is fastened hip replacement is fixed in the thigh bone (femur) to the rib cage. with traditional hammering familiar to orthopaedic surgeons. The M-COR is a modular design with Patterson Tables Embryonic Stem a distinct neck component for improved fit and Cell Bill adjustability. Portland has moved to full capacity manufacturing and is taking measures to licence off- Liberal backbencher, Senator Kay Patterson. site manufacturing to improve inventories. tabled her promised private member’s bill on embryonic stem cell research and therapeutic cloning. “Demand from Plus Orthopedics is exceeding The proposed amendments to current legislation expectations as the first US surgeons are choosing to outlawing therapeutic cloning closely follow the implant more M-COR hips than we expected,” said recommendations of the Lockhart Review. Patterson Mr David Sekel, CEO of Portland Orthopaedics. said the amendments would maintain a strong and “Portland’s priority is to immediately boost Bi Board manufacturing capacity to meet the expanding joint R&D to commercialize its MD Keeper wrist replacement range and meet the growing demand.” device that can monitor patients’ physical information Professor Colin Masters Receive • ALS Drug Compound Delivery • Neusrosciences Victoria and Israel’s Shizim the Lewis K. Black International are collaborating to develop a new way Prize to treat motor neurone disease, Amyotrophic Professor Colin Masters, of the Department of Lateral Sclerosis (ALS) Pathology, University of Melbourne and co-founding • Interactive Health and Wellbeing Portal scientist and Director of Prana Biotechnology Limited • Victorian company Health First and Israel- will receive the Lewis K. Black International Prize based Card Guard are developing an in-home for Excellence in Biomedical Research, presented blood glucose monitoring system with wireless by Thomas Jefferson University. The Lewis K. Black data transmission to a central database International Prize in Medicine is awarded biennially • Dairy Farming Practices Software in recognition of the impact, either accomplished or • Victorian company, Milka-Ware and Israeli potential, of pioneering biomedical research on the based Afikim are developing strategic software alleviation of human disease and suffering. that measures and analyzes milking variables in order to improve the productivity of dairy farms “Professor Masters’ receipt of this prestigious award offers further validation of the absolute credibility of the Prana scientific team,” said Geoffrey Victorian Medical Research Kempler, Chairman and Chief Executive Officer of Institutes Receive A $26M Boost Prana Biotechnology. “For over 30 years, Colin has The Victorian Government announced A$26 dedicated his research to the study of the nature million for 15 Victorian medical research institutes of Alzheimer’s disease with the hope of finding an through the Operational Infrastructure Support effective treatment.” Program (OISP). The infrastructure grants support His current research studies on Alzheimer’s the laboratories, equipment and facilities that are disease are focused on identifying compounds, such vital to achieving Victoria’s breakthroughs in medical as PBT2 (Prana’s lead compound), that can inhibit research. Minister Brumby used the announcement to the production or aggregation of amyloid in the highlight the work undertaken by the Ludwig Institute Alzheimer’s diseased brain. PBT2 is scheduled to for Cancer Research (LICR), one of the beneficiaries commence a Phase II clinical trial in Sweden. of the OISP and the Royal Melbourne Hospital. The team has been analyzing clinical records on 1,500 bowel cancer patients collected in the Bio21 Molecular Victorian and Israeli Companies Medicine Informatics Model (MMIM) database. Announce Collaborations The MMIM was established in 2002 and is being On 19 September the Minister for Innovation, rolled out across all Victorian metropolitan and Mr Brumby announced A$1 million for regional cancer centres to develop the Australian commercialization collaborations between Victorian Cancer Grid with A$11 million State funding and Israeli companies. The four projects to be funded announced in Healthy Futures Life Science Statement under VISTECH include: launched in April 2006. • Victoria-Israel Telehealth Expert System Through the database, researchers have identified (VITEX) new information about links between: • Tadiran Lifecare an Israeli company has • Diabetes and bowel cancer; teamed with Melbourne-based Siemens • Treatment of non-English speaking people and Australia, to undertake clinical trials and further cancer; Bi Board • The age of patients and treatments they in China. China’s first official database for academic receive and journals became operational recently. A key national • Diet, lifestyle factors and cancer. web project, the search program built at a cost of 345 million yuan US$43 million provides the contents of 6,642